Long Non Coding RNA Based Regulation of Cerebrovascular Endothelium

Samatha Mathew1,2 and Sridhar Sivasubbu1,2*

1CSIR Institute of Genomics and Integrative Biology (CSIR-IGIB), New Delhi, India, 2Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India

The rapid and high throughput discovery of long non coding RNAs (lncRNAs) has far outstripped the functional annotation of these novel transcripts in their respective cellular contexts. The cells of the blood brain barrier (BBB), especially the cerebrovascular endothelial cells (CVECs), are strictly regulated to maintain a controlled state of homeostasis for undisrupted brain function. Several key pathways are understood in CVEC function that lead to the development and maintenance of their barrier properties, the dysregulation of which leads to BBB breakdown and neuronal injury. Endothelial lncRNAs have been discovered and functionally validated in the past decade, spanning a wide variety of regulatory mechanisms in health and disease. We summarize here the lncRNA-mediated regulation of established pathways that maintain or disrupt the barrier property of CVECs, including in conditions such as ischemic stroke and glioma. These lncRNAs namely regulate the tight junction assembly/disassembly, angiogenesis, autophagy, apoptosis, and so on. The identification of these lncRNAs suggests a less understood mechanistic layer, calling for further studies in appropriate models of the blood brain barrier to shed light on the lncRNA-mediated regulation of CVEC function. Finally, we gather various approaches for validating lncRNAs in BBB function in human organoids and animal models and discuss the therapeutic potential of CVEC lncRNAs along with the current limitations.

Keywords: long non coding RNAs, blood brain barrier, neurovascular unit, cerebrovascular endothelial cells, organoids, animal models, lncRNA therapeutics

INTRODUCTION

Endothelial cells (ECs) lining the blood vessel walls display functional, structural and biochemical heterogeneity across the body, depending on the cellular environment and blood flow ((Aird, 2007a), (Aird, 2007b)). Using endothelial cell-specific translating ribosome affinity purification, a recent study cataloged the in vivo translatomes of ECs of mice, showing the endothelial heterogeneity across vascular beds (Cleuren et al., 2019). Spatial transcriptomics of the brain in a cerebral cavernous malformation (CCM) mouse model could identify the differential involvement of arterial ECs versus venous ECs in the disease (Orsenigo et al., 2020). Endothelial cells also exhibit considerable plasticity in response to a variety of endothelial permeability modulators (Claesson-Welsh et al., 2021). Moreover, tissue-specific phenotype of the endothelium is not only decided by the environmental milieu, but is encoded by epigenetic marks as well (Aird, 2007a). The discovery of non-coding RNA (ncRNA) mediated regulation of epigenetic modifications and other cellular processes provide new
avenues to explore the mechanisms of heterogeneity and plasticity of endothelial cells. With the availability of single cell endothelial transcriptomic data (Khan et al., 2019), there are many prospects ahead to decipher the complex network of the noncoding RNA and protein coding factor interplay in endothelial cells.

**CEREBROVASCULAR ENDOTHELIAL CELLS**

The heightened sensitivity of the brain tissue and neuronal signaling to pathogens, toxins and ionic imbalance, coupled with the inability to rapidly regenerate post damage has led to the evolution of a highly selective blood brain barrier (BBB) between blood and the brain parenchyma (Strange, 1992). Cerebrovascular endothelial cells (CVECs) are non-fenestrated, with exceptions in certain areas of the brain, and undergo very low rates of transcytosis allowing only lipid soluble molecules to pass through, sieving the movement of water-soluble solutes. CVECs are marked by abundant tight junctions at endothelial cell-cell boundaries, and express a large number of efflux proteins to exclude toxins and fewer leukocyte adhesion molecules to prevent inflammation. Additionally, they contain higher numbers of mitochondria (Obermeier et al., 2013; Daneman and Prat, 2015).

The cellular anatomy of the blood brain barrier consists of a conjugated system of endothelial cells, mural cells and glial cells, along with the basement lamina and glycocalyce. The signals sent by supporting cells to the endothelial cells determine the composition and permeability of the blood brain barrier. The signaling of the support cells are also influenced by the triggers from neurons (Obermeier et al., 2013). This neurovascular unit (NVU) is maintained throughout the life of a vertebrate for the normal functioning of the brain. The cerebrovascular endothelial cells rapidly respond to cues from the NVU, from both the luminal and abluminal sides. Apart from the regulation of angiogenesis and permeability during development by neurons, in adults, neuronal activity can send signals that affect the BBB permeability during stresses such as chronic sleep deprivation (Sweeney et al., 2019). In addition, in neuroinflammatory conditions such as ischemic stroke and psychiatric disorders, several cues lead to alteration in BBB permeability (Yang et al., 2019; Kealy et al., 2020).

**INTERPLAY OF MOLECULAR PATHWAYS IN CVEC FUNCTION**

During development, the Vascular Endothelial Growth Factor (VEGF) pathway is central to guidance and migration of endothelial cells into the neural tissue, during which time they possess tight junctions and transporter proteins, however with high levels of transcytosis and expression of leukocyte adhesion molecules (Bauer et al., 2014). Wnt/beta-catenin signaling pathway is specifically activated in the central nervous system (CNS), and regulates expression of nutrient transport molecules. The sonic hedgehog pathway further plays a role in the maintenance of the barrier properties (Obermeier et al., 2013). Signals from the pericytes and astrocytes and basement membrane also influence the maintenance of BBB (Daneman et al., 2010; Obermeier et al., 2013). The different cellular pathways involved in BBB establishment and permeability have been summarized recently (Tjakra et al., 2019).

**THE UNKNOWNS OF BBB: CAN LONG NON CODING RNA ANSWER?**

An elegant set of questions on the dynamicity of BBB have been raised by the Daneman group recently (Profaci et al., 2020). It is well understood that the BBB is not uniform in different parts of the brain and that the “breakdown” of BBB is also a non-uniform process. The non-coding RNA mediated regulation of the NVU has been known for more than a decade (Wang S.-W. et al., 2018). LncRNAs can exert a regulatory role at epigenetic, post-transcriptional, translational and post-translational levels (Xie and Wei, 2021), (Huang et al., 2021) while some lncRNAs are also known to function by coding for short peptides (Choi et al., 2019), (Hartford and Lal, 2020). LncRNAs are in particular known to be highly cell-type specific, unlike mRNA (Quinn and Chang, 2016), which could act as a potential factor in the variability of endothelial cells in general and variability within brain endothelial cells depending on brain region, age and disease conditions. Also, the abundance of a lncRNA can influence its functional role, which can add another tier of fine-tuning for cell-type specific properties (Grammatikakis and Lal, 2021). The tissue-specific transcriptomic and epigenomic signatures that...
differentiate CNS endothelial cells and other endothelial cells have been explored earlier (Sabbagh et al., 2018). The availability of transcriptomic data from the NVU at single cell resolution further opens up avenues to uncover novel regulators of cell function, including the less abundantly expressed lncRNAs (Kiss et al., 2020), (Mäe et al., 2021). In this review, we particularly focus on functionally validated lncRNAs associated with cerebrovascular endothelial cell pathways.

**LONG NON CODING RNAs IN ENDOThelial FUNCTION**

Of the thousands of RNAs in a eukaryotic cell that defy the central dogma of biology, long non coding RNAs (lncRNAs) form a considerable proportion. NONCODEv5 has put together nearly 550 thousand lncRNA transcripts from 17 species, of which 172 thousand are of human origin (Fang et al., 2018). The ANGIOPENES database has catalogued protein coding RNAs and noncoding RNAs in endothelial cells from human, and the model organisms, mouse and zebrafish (Müller et al., 2016). Endothelial lncRNAs are known in development, function and vascular disease (Kok and Baker, 2019), (Jaé and Dimmeler, 2020). A recent review has classified vascular-associated lncRNAs based on their mechanism of action (Ono et al., 2021). Here we introduce some recent studies to spotlight the diverse regulation of endothelial function by lncRNAs:

The lncRNA **PUNISHER or AGAP2-ASI** is enriched in small extracellular vesicles (sEV) released by endothelial cells in the plasma of coronary artery disease (CAD) patients. **PUNISHER** interacts with **Heterogeneous Nuclear Ribonucleoprotein K (hnRNPK)**, an RNA binding protein, and subsequently regulates the levels of VEGFA and endothelial cell proliferation in sEV recipient endothelial cells (Hosen et al., 2021). Another recent report shows lncRNA **NORAD** has a detrimental effect in CAD models by facilitating endothelial cell injury. **NORAD** is a nuclear lncRNA known to have multiple binding partners earlier, but in the said study was found to bind to HDAC6, through the RNA binding protein FUS. The **NORAD-FUS-HDAC6** complex leads to H3K9 deacetylation at VEGF promoter and suppresses its transcription. The effects of **NORAD** on endothelial cell injury were also demonstrated in atherosclerotic mice (Kai et al., 2021). In an oxidized LDL (oxLDL)-induced aortic endothelial cell model of atherosclerosis, the knockdown of lncRNA **AK087124** inhibited apoptosis and inflammation. **AK087124** acts as a sponge for **mir-224-5p**, which targets PTEN, a pro-apoptotic factor in the atherosclerotic model of aortic endothelial cells (Zhai et al., 2021).

LncRNA **VEAL2** was shown to interact with the kinase Protein kinase C beta 2 (PRKCB2) and prevent hyper-activation of the kinase by the small molecule diacylglycerol (DAG). This interplay regulates the turnover of junctional proteins VE-cadherin and beta-catenin, altering the permeability and angiogenic properties of human umbilical vein endothelial cells (HUVECs). **VEAL2** was found to be upregulated in the blood of diabetic retinopathy patients, and overexpression of the lncRNA in hyperglycemia model of HUVECs could attenuate PRKCB2-mediated hyper-permeability. A zebrafish knockout model for the ortholog **veal2** caused cranial hemorrhage, which could be rescued by the PRKCB2 inhibitor Enzastaurin (Sehgal et al., 2021). Aging related lncRNA **AERRIE** is important to maintain endothelial function and angiogenesis in vitro. Silencing of **AERRIE** led to DNA damage response mediated by YBX1. The study showed further that depletion of **AERRIE** induced DNA damage, and the damage response was activated by YBX1 as a consequence. Rescue with **AERRIE** could improve DNA repair in a doxorubicin mediated DNA damage model of endothelial spheroids (Pham et al., 2020). Endothelial-cell enriched lncRNA **LINC00961** encodes a micropeptide Small regulatory polypeptide of amino acid response (SPAAR). Knockdown of **LINC00961** in HUVECs prevents cell proliferation and angiogenesis. The lncRNA alone prevents angiogenesis while SPAAR induces vessel network formation and increases permeability, indicating that both the lncRNA and micropeptide have distinct functional roles, with independent protein partners (Spencer et al., 2020).

**THE EVOLVING ROLES OF LncRNA IN BBB FUNCTION**

A plethora of noncoding RNAs are known to govern the BBB function and dysfunction, including small, long and circular non coding RNAs (Wang S.-W. et al., 2018), (Liu et al., 2021), (Gan et al., 2020). LncRNAs in BBB dysfunction have been extensively reported, with a view of identification of potential biomarkers. Here we attempt to collate the mechanistic role of lncRNA expressed in cerebrovascular endothelial cells and how they elicit regulation in known pathways.

**CVE LncRNAs Involved in Tight Junction Dynamics**

Tight junctions (TJs) allow CVECs to form a size and charge selective barrier and many membrane complexes are assembled around TJs, helping in cell signaling and polarization of the endothelial cells. Three types of transmembrane proteins comprise TJs: Claudins, MARVEL-motif containing proteins such as occludin and immunoglobulin super family membrane proteins such as junctional adhesion molecule (JAM) isoforms. BBB usually contains claudin-3, 5 or 12, claudin-5 being the most abundant. Claudins interact with zona occludens (ZO) proteins via their C- terminals and their turnover is determined by phosphorylation marks. Zona occludens 1, 2 and 3 act as scaffold proteins and are instrumental in the formation of TJs, with ZO-1 and ZO-2 present in endothelial cells. Occludin interacts with the ZO proteins and cytoskeleton. Phosphorylation mediated marking of degradation of occludin regulates the permeability of the barrier. JAM B and C are known to be endothelial specific and loss of JAM-C causes cerebral hemorrhage. JAMs also mediate the transcellular migration of leukocytes in endothelial cells. The downregulation of TJ proteins have been reported in BBB disruption (Bauer et al., 2014). Several
lncRNAs have been reported to regulate TJ protein levels and can affect barrier permeability and trans-endothelial electrical resistance (TEER).

Lnc00462717 regulates levels of occludin in a blood-tumor barrier (BTB) model of brain microvascular endothelial cells (BMECs) by binding to polyproteinidicinade t binding protein (PTBP1) and downregulating miR-186-5p. miR-186-5p directly binds to occludin 3’UTR and regulates its expression levels, thus altering the endothelial permeability (Zhang C. et al., 2020). LncRNA HOTAIR interacts with transcription factor upstream stimulatory factor 1 (USF1) and regulates levels of ZO-1, claudin-5 and occludin. miR-148b-3p binds to HOTAIR and USF1 transcripts and modulates the levels of the TJs proteins (Sa et al., 2017).

Linc00174 titer levels the expression levels of the FOS Like 2, AP-1 Transcription Factor (FOSL2), which can regulate expressions of ZO-1, occludin and claudin-5. MicroRNAs miR-138-5p and miR-150-5p bind to both Linc00174 and FOSL2 transcripts and bring down their levels, increasing permeability in the BTB model. It was seen that FOSL2 also has a feedback loop with Linc00174 and binds to its promoter (Guo et al., 2019). NEAT1 is a miRNA sponge of miR-181d-5p which regulates levels of KY-Box Transcription Factor 5 (SOX5) by binding to its 3’ UTR. SOX5 modulates levels of the tight junction proteins ZO-1, occludin and claudin-5 and thus NEAT1 regulates BTB permeability (Guo et al., 2017).

LncRNA MIAIT acts as a competing endogenous RNA (ceRNA) for miRNA miR-140-3p. ZO-1-associated kinase (ZAK) which phosphorylates Nfxb-p65 is a target of miR-140-3p. NFkB-p65 is a transcription suppressor for the TJs proteins ZO-1, occludin, and claudin-5 (He et al., 2020). LINC00094 sponges miR-224-5p/miR-497-5p in an Alzheimer’s disease (AD) microenvironment BBB model. miR-224-5p/miR-497-5p regulates Endophilin-1 post-translationally, which is a known factor in modulation of BBB permeability by altering expressions of ZO-1, claudin-5 and occludin through mEGFR/ERK1/2 pathway (Zhu et al., 2019). LncRNA XIST is downregulated on ischemic insult while it is upregulated in the post-ischemic phase in patients and in a mouse model of cerebral ischemic stroke. In oxygen-glucose deprivation and restoration (OGD/R) model of ischemia and stroke, leading to BBB disruption (Bai et al., 2005). LncRNA Xist was shown that FOSL2 also has a feedback loop with XIST 5p which targets VEGFA (Yan B. et al., 2015). LncRNA Meg8 is expressed in high levels in OGD challenged BMECs and its silencing inhibits proliferation and angiogenesis. Silencing of Meg8 could be correlated with lower levels of VEGFA. Meg8 acts as a sponge for miR-130a-5p which targets VEGFA. Injection of Meg8 could diminish cerebral infarct volumes in middle cerebral artery occlusion (MCAO) model in rats (Sui et al., 2021).

LncRNA MIAIT knockdown reduced levels of VEGF in HUVECs and reduced microvessel number and showed reduction in TJs in brains of an AD mouse model (Jiang et al., 2016). MIAIT is a ceRNA sponge for miR-150-5p, which targets VEGF ((Yan B. et al., 2015). LncRNA Meg8 is expressed in high levels in OGD challenged BMECs and its silencing inhibits proliferation and angiogenesis. Silencing of Meg8 could be correlated with lower levels of VEGFA. Meg8 acts as a sponge for miR-130a-5p which targets VEGFA. Injection of Meg8 could diminish cerebral infarct volumes in middle cerebral artery occlusion (MCAO) model in rats (Sui et al., 2021).

LncRNA Snhgl1 which expresses abundantly in cerebral microvessels of ischemic mouse model and OGD induced BMECs is a ceRNA for miR-18a. Hypoxia-inducible factor 1-alpha (HIF1A) mediated activation of VEGF pathway is regulated by the Snhgl1/miR-18a axis by the binding of miR-18a to suppress HIF1A expression and to determine the apoptosis and homeostasis of BMECs (Zhang L. et al., 2018). Snhgl1 is also known to act as a sponge for miR-199a in the OGD/R BMEC model, which can downregulate both HIF1A and VEGF and inhibit capillary formation by BMECs (Wang Z. et al., 2018). A
third miRNA, miR-338 is also sponged by lncRNA Snhg1 in OGD-treated BMVECs. miR-338 binds to 3’ UTR of HIF1A and induces apoptotic pathways in the BMEC model of ischemia (Yang and Zi, 2019).

**CVE LncRNAs in PI3K-Akt Pathway**

Depending on the factor that activates PI3K/Akt pathway, and the downstream effector of Akt, the outcomes of endothelial permeability can vary through assembly or disassembly of TJs (Cong and Kong, 2020). For instance, in ischemic hypoxia in rat neonates, the hematopoietic factor Granulocyte stimulating factor (G-CSF) activates PI3K/Akt/GSK-3β axis to increase BBB barrier properties and is anti-inflammatory. The authors of the study note that the protective effects of PI3K/Akt pathway were shown previously, which is mediated by reducing levels of VCAM-1, ICAM-1 and beta catenin, while upregulating claudin 3 and 5 (Li et al., 2015). On the contrary, in a rat model of brain injury and a parallel in vitro hypoxic model, PI3K/Akt/GSK-3β axis activation led to apoptosis of brain endothelial cells (Chen et al., 2017). Certain lncRNAs elicit the PI3K/Akt pathway to exert their regulatory action on CVECs.

LncRNA MALAT1, a ceRNA for miR-126 in the OGD model of ischemia in human (HBMECs), has a positive effect on angiogenesis and cell viability via regulating PI3K-Akt pathway activation. MALAT1 leads to endothelial cell apoptosis and inhibition of PI3K-Akt pathway in OGD HBMECs by sponging miR-126 (Zhang L. et al., 2020). LncRNA FAL1 has a protective effect against oxidative stress in OGD/R challenged HBVMECs. FAL1 overexpression inhibits expressions of interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1) and high mobility group box 1 (HMGBl). Further, FAL1 overexpression restored lowered phosphorylation levels of p21 (RAC1) activated kinase 1 (PAK1) and Akt in the OGD/R cells, and increased expression of proliferating cell nuclear antigen (PCNA), a downstream target. Thus, FAL1 overexpression reversed cell injury induced by OGD/R (Gao M. et al., 2020).

**CVE IncRNAs in STAT3 Activation**

Sphingosine-1-phosphate (SIP) pathway is activated in OGD/R and MCAO models of cerebral ischemia. Signal Transducer And Activator Of Transcription 3 (STAT3) gets activated downstream of SIP pathway and its inhibition protects BBB from OGD/R induced dysfunction (Nakagawa and Aruga, 2020). JAK/STAT3 pathway induction and microRNA mediated regulation of SIP receptor was also shown to cause BBB damage in rat model of septic encephalopathy (Chen S.-L. et al., 2020). Following are two examples of CVE IncRNAs with the potential to activate STAT3.

The abundant expression of IncRNA Snhg3 in the BMVEC model of intracerebral hemorrhage (ICH) led to inhibition of proliferation and migration, apoptosis and loss of barrier properties. Snhg3 overexpression increased levels of Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) mRNA and protein and its receptor fibroblast growth factor-inducible 14 (Fn14). This then activated the STAT3 pathway by phosphorylation of STAT3 protein. STAT3 pathway activation led to the secretion of MMP-3 and MMP-9, increasing permeability. Combined inhibition of TWEAK, Fn14 and STAT3 could reverse effects of high expression of Snhg3 in ICH BMVECs (Zhang J. et al., 2019). LncRNA Malat1 knockdown reversed the upregulation of 15-lipoxygenase 1 (15-LOX1), pSTAT3 and VEGF in OGD/R BMVECs. This suggested that Malat1 induces angiogenesis through activation of STAT3 pathway in OGD/R BMVECs (Wang C. et al., 2019).

**CVE LncRNAs in Autophagy**

The process of autophagy is a systematic house-keeping process to remove damaged organelles or misfolded proteins by lysosomal degradation and in case of irreparable damage, the self-destruction of cells containing those (Mathiassen et al., 2017). Occludin degradation and subsequent increase in permeability has been shown to be induced via autophagy in OGD/R treated bEnd.3 cells and MCAO rat models (Kim et al., 2020). Autophagy mediated degradation of ZO-1 is known in high glucose conditioned BMVECs in the OGD/R model (Zhang S. et al., 2018). Alternatively, protective effect of autophagy in OGD/R BMVECs by redistribution of ZO-1 on the membrane has also been shown (Li H. et al., 2014). In short term hypoxia injury, autophagy protects cerebrovascular endothelial cells from increased permeability and loss of TEER. Effect of autophagy in endothelial damage during ischemic stroke has been reviewed earlier (Kim et al., 2018). A couple of lncRNAs are known to modulate CVEC function through the regulation of the autophagy pathway.

In the OGD/R model of BMVECs, Malat1 sponges miR-26b which in turn regulates Unc-51 Like Autophagy Activating Kinase 2 (ULK2). Knockdown of ULK2 prevents autophagy in OGD/R BMVECs. Hence Malat1 acts as a protective agent in OGD/R by activating autophagy (Li Z. et al., 2017). Additionally in OGD induced bEnd.3 cells, Malat1 is shown to act as a sponge for miR-200c-3p which binds to Sirtuin 1 (SIRT1) mRNA. Knockdown of SIRT1 inhibited LCB3II and increased p62 expression and increased cell death in bEnd.3 OGD/R cells. By maintaining the levels of SIRT1, Malat1 protects bEnd.3 cells from cell death by inducing autophagy (Wang S. et al., 2019). LncRNA PVT1 negatively regulates miR-186 in glioma endothelial cells. PVT1 overexpression induces formation of autophagosomes in the BTB model. miR-186 binds to 3’ UTRs of Autophagy related 7 (Atg7) and Beclin1, preventing autophagy, while PVT1 reverses this effect and facilitates endothelial cell autophagy in the BTB model (Ma et al., 2017a).

**CVE LncRNAs in Apoptosis**

Once the vessels migrate into the nascent neural tissue, and the formation of the neural tissue is complete, the associated endothelial cells become quiescent. Apoptosis plays a major role in homeostasis of quiescent BMVECs by removal of the dysfunctional cells. Apoptotic signals also directly regulate angiogenesis, and are particularly important during adult neurogenesis coupled with angiogenesis (Pozhilenkova et al., 2017). In disease conditions like stroke, apoptosis of BMVECs leads to neuronal injury via increased BBB permeability and leads to vascular edema. Apoptosis of CVECs can occur through both intrinsic and extrinsic pathways of apoptosis, owing to various
| LncRNA Name | Associated Pathway in Cerebrovascular Endothelial Cells | Interacting Partner | Effect on BBB | Mechanism | Disease/Condition | Model | References |
|-------------|--------------------------------------------------------|---------------------|--------------|-----------|------------------|-------|------------|
| Lnc00462717 | Tight junction turnover | PTBP1 | + | Regulation of occludin levels | Glioma | Co-culture BTB model | Zhang et al. (2020a) |
| HOTAIR | Tight junction turnover | miR-148b-3p | + | Modulation of ZO-1, claudin-5 and occludin levels | Glioma | Co-culture BTB model | Sa et al. (2017) |
| XIST | Tight junction turnover | miR-137 | + | Modulation of levels of ZO-2 and CXCR7 | Glioma | Co-culture BTB model | Yu et al. (2017) |
| TUG1 | Tight junction turnover | miR-144 | + | Modulation of ZO-1, claudin-5 and occludin levels | Glioma | Co-culture BTB model | Cai et al. (2015) |
| MALAT1 | Tight junction turnover | miR-140 | + | Modulation of ZO-1, claudin-5 and occludin levels | Glioma | Co-culture BTB model | Ma et al. (2016) |
| Linc00174 | Tight junction turnover | miR-138-5p and miR-150-5p | + | Modulation of ZO-1, claudin-5 and occludin levels | Glioma | Co-culture BTB model | Guo et al. (2019) |
| NEAT1 | Tight junction turnover | miR-181daysay-5p | + | Modulation of ZO-1, claudin-5 and occludin levels | Glioma | Co-culture BTB model | Guo et al. (2017) |
| MEG3 | Tight junction turnover | miR-330-5p | - | Modulation of ZO-1, claudin-5 and occludin levels | Glioma | Co-culture BTB model | Shen et al. (2018) |
| MtAT | Tight junction turnover | miR-140-3p | - | Modulation of ZO-1, claudin-5 and occludin levels | Glioma | Co-culture BTB model | He et al. (2020) |
| LINC00094 | Tight junction turnover | miR-224-5p/miR-497-5p | - | Modulation of ZO-1 and occludin levels | Alzheimer’s disease microenvironment | Co-culture BTB model | Zhu et al. (2019) |
| LncRSPH9-4 | Tight junction turnover | miR-17-5p | - | Modulation of ZO-1 and occludin levels | Meningitic E. coli Infection | Human BMECs | Xu et al. (2021a) |
| Xist | Tight junction turnover | miR-92a | + | Modulation of ZO-1 and claudin-5 occludin levels | Cerebral ischemia | OGD/R murine brain endothelial cells and bEnd.3 cells | Wang et al. (2021a) |
| Miat | VEGF pathway, Tight junction turnover | None | + | Modulation of ZO-1 and occludin levels | Alzheimer's disease | Mice | Ji et al. (2016) |
| Meg3 | VEGF pathway | None | * | Modulation of VEGF levels in brain | MEG3 knockout | MEG3 null mice | Gordon et al. (2013) |
| Anrli | VEGF pathway | None | * | Modulation of VEGF levels in brain | Diabetes mellitus with cerebral infarction | Rats | Zhang et al. (2017a) |
| MALAT1 | VEGF pathway | miR-205-5p | * | Modulation of VEGF levels | Cerebral ischemia | OGD/R HBMECs | Gao et al. (2020a) |
| Snhg12 | VEGF pathway | miR-150 | * | Modulation of VEGF levels | Cerebral ischemia | OGD/R bEnd.3 cells, MCAO mice | Zhao et al. (2018) |
| SNHG15 | VEGF pathway | miR-153 | * | Modulation of VEGFA levels | Cerebral ischemia | Gliaoma-conditioned hOMECs | Ma et al. (2017b) |
| Meg8 | VEGF pathway | miR-130a-5p | * | Modulation of VEGFA levels | Cerebral ischemia | OGD bEnd.3 cells, MCAO rats | Sui et al. (2021) |
| Snhg1 | Hypoxia pathway | miR-18a | * | Modulation of HIF1A levels | Cerebral ischemia | OGD mice BMECs, MCAO mice | Zhang et al. (2018a) |
| Snhg1 | VEGF-Hypoxia pathway | miR-199a | * | Modulation of VEGF and HIF1A levels | Cerebral ischemia | OGD/R model of mice BMECs | Wang et al. (2018b) |
| Snhg1 | Hypoxia pathway | miR-338 | * | Modulation of HIF1A levels | Cerebral ischemia | OGD mice BMECs | Yang and Z, (2019) |
| MALAT1 | PI3K-Akt pathway | miR-126 | * | Activation of PI3K and Akt | Cerebral ischemia | OGD human BMECs | Zhang et al. (2020b) |
| FAL1 | PAK1-Akt pathway | None | * | Activation of PAK1 and Akt | Cerebral ischemia | OGD/R human BMECs | Gao et al. (2020c) |
| Snhg3 | STAT3 pathway | None | * | Activation of STAT3 | Intracerebral hemorrhage | ICH rats, OGD plus themin rat BMECs | Zhang et al. (2019a) |
| Malat1 | STAT3 pathway | None | * | Activation of 15-LOX1/STAT3 pathway | Cerebral ischemia | OGD/R mice BMECs, MCAO mice | Wang et al. (2019a) |
| Malat1 | Autophagy | miR-26b | * | Modulation of ULK2 levels | Cerebral ischemia | OGD/R mice BMECs | Li et al. (2017b) |

(Continued on following page)
TABLE 1 | (Continued) List of lncRNAs expressed in cerebrovascular endothelial cells and their functional roles.

| LncRNA Name | Associated Pathway in Cerebrovascular-Endothelial Cells | Interacting Partner | Effect on BBB | Mechanism | Disease/Condition | Model | References |
|-------------|--------------------------------------------------------|---------------------|--------------|------------|-------------------|-------|------------|
| Malat1      | Autophagy                                              | miR-200c-3p         | *            | Modulation of SIRT1 levels | Cerebral ischemia | OGD bEnd.3 cells | Wang et al. (2019b) |
| PVT1        | Autophagy                                              | miR-186             | *            | Modulation of Agt7 and Bed11 levels | Gloma | Gloma-conditioned human CMECs, MCAO mice | Ma et al. (2017a) |
| Malat1      | Apoptosis                                              | Bim and E-selectin  | *            | Modulation of Bim levels and pro-inflammatory cytokines | Cerebral ischemia | OGD mice BMECs, MCAO mice | Zhang et al. (2017b) |
| Malat1      | VEGF pathway, Apoptosis                                | miR-143             | *            | Modulation of VEGF, ET-1, vWF, and MMP-9 levels | Intracranial aneurysm | IA rats, Vascular endothelial cells from IA rat tissue | Gao et al. (2020b) |
| MALAT1      | Apoptosis                                              | none                | *            | Modulation of MDM2, p53 and BAX levels | Cerebral ischemia | OGD/R human BMECs, MCAO mice | Zhang et al. (2018c) |
| SNHG16      | Apoptosis                                              | miR-15a-5p          | *            | Modulation of Bcl-2 levels | Cerebral ischemia | OGD/R human BMECs | Teng et al. (2020) |
| LncOGD-1006 | Apoptosis                                              | miR-184-5p          | *            | Modulation of CAAP1 levels | Cerebral ischemia | OGD bEnd.3 cells | Chen et al. (2020a) |
| Neat1       | Apoptosis, VEGF pathway                                | miR-377             | *            | Modulation of SIRT1, VEGF, and BCL-XL levels | Cerebral ischemia | OGD mice BMECs | Zhou et al. (2019) |
| Meg3        | Apoptosis, VEGF pathway, Hypoxia pathway               | p53                 | *            | Modulation of p53 and NOX4 levels | Cerebral ischemia | OGD/R rat BMVECs | Zhan et al. (2017) |
| FENDRR      | Apoptosis, VEGF pathway                                | miR-126             | *            | Modulation of VEGFA levels | Hypertensive | Human BMECs treated with thrombin | Dong et al. (2018) |
| Gas5        | Apoptosis                                              | miR-34b-3p          | *            | Modulation of EPHA4 levels | Cerebral ischemia | OGD/R bEnd.3 cells | Shen et al. (2021) |
| Snhg1       | Apoptosis                                              | miR-298             | *            | Modulation of SIK1 levels | Cerebral ischemia | OGD/R bEnd.3 cells | Zhou et al. (2021) |
| Rmst        | Apoptosis                                              | miR-150             | *            | Modulation of MMP2 and MMP9 levels, change in caspase-3 activity | Cerebral ischemia | OGD bEnd.3 cells | Qiao et al. (2020) |
| RMST        | Apoptosis                                              | miR-204-5p          | *            | Modulation of VCAM1 levels | Cerebral ischemia | OGD human BMECs and bEnd.3 cells | Yin et al. (2021) |
| Miat        | Apoptosis                                              | MYC                 | *            | Modulation of ENC1 levels | Intracranial aneurysm | Vascular endothelial cells HBECS-5, IA rats | Li et al. (2020) |
| Meg3        | Ferroptosis                                            | None                | *            | Modulation of p53 and BAX levels | Cerebral ischemia with hyperglycermia | OGD rat BMVECs with hyperglycermia | Chen et al. (2021b) |
| H19         | Ferroptosis                                            | miR-106b-5p         | *            | Modulation of ACSL4 levels | Intracerebral hemorrage | ICH human BMVECs | Chen et al. (2021a) |
| LINC00346   | Angiogenesis                                            | ANKH1D1             | *            | Modulation of EGFL7 and ROBO4 levels | Gloma | Gloma-conditioned human CMECs | Yang et al. (2020) |
| Dancr       | Angiogenesis                                            | miR-33a-5p          | *            | Modulation of XB1 levels | Cerebral ischemia | OGD rat BMVECs | Zhang et al. (2020c) |
| Miat        | Angiogenesis                                            | miR-204-5p          | *            | Modulation of HMG1B levels | Cerebral ischemia | OGD rat CMECs, MCAO mice | Deng et al. (2020) |

BTB, blood tumor barrier; BMECs/BMVECs, brain microvascular endothelial cells; OGD/R, oxygen-glucose deprivation and restoration; OGD, oxygen-glucose deprivation; MCAO, middle cerebral artery occlusion; CMECs, cerebral microvascular endothelial cells; IA, intracranial aneurysm. Effect on BBB is represented as + (maintains the BBB); − (induces BBB permeability), * (no information in the study).

stimuli such as infections, amyloid proteins, inflammation, ischemia, and so on. Studies have shown that elevated levels of p53 and Bax, lower levels of Bcl-2, and activation of caspase-3 bring about apoptosis in BMECs. The ERK, JNK and p38-MAPK pathways are implicated in apoptosis induction in BMECs (Rizzo and Leaver, 2010). Several lncRNAs are known to perform anti-apoptotic or pro-apoptotic roles to determine outcomes of cerebrovascular endothelial cells in disease conditions.

Malat1 is upregulated in the OGD model of BMECs and cerebral microvessels of ischemic mice after reperfusion. Knockout of Malat1 amplifies ischemic injury in mice model. Malat1 has an anti-apoptotic role in cerebral microvasculature by regulating the expression of the pro-apoptotic factor Bim. Malat1 knockdown also increased levels of inflammatory cytokines like E-Selectin, MCP1 and IL-6. Further, Malat1 was shown to directly interact with both Bim and E-selectin proteins (Zhang...
LncRNA SNHG16 acts as a sponge for miR-15a-5p in OGD/R HBMECs. miR-15a-5p binds to and targets Bcl-2 post transcriptionally. Hence SNHG16 protects HBMECs from OGD/R apoptosis (Teng et al., 2020).

LncOGD-1006 is upregulated in OGD BMECs and is protective against apoptosis. Overexpression of LncOGD-1006 increased expression of Bcl-2 and BCL2 associated agonist of cell death (BAD) proteins and downregulated cleaved caspase-3. miR-184-5p is sponged by LncOGD-1006 which regulates expression of Caspase Activity And Apoptosis Inhibitor 1 (CAAP1). CAAP1 knockdown reversed effects of LncOGD-1006 overexpression (Chen JY. et al., 2020).

LncRNA Neat1 was upregulated in OGD BMECs and is a sponge for miR-377. Knockdown of Neat1 leads to apoptosis in OGD BMECs, increasing BAX expression and downregulating VEGF, SIRT1 and Bcl-xl. miR-377 was shown to bind to 3′UTRs of VEGF, SIRT1 and Bcl-xl and hence Neat1 acts anti-apoptotic by sponging miR-377 (Zhou et al., 2019).

LncRNA Meg3 knockdown protects rat BMECs (RBMVECs) from OGD/R mediated apoptosis. Meg3 directly interacts with p53 and modulates its downstream targets. The study showed that the p53 target NADPH Oxidase 4 (NOX4) expression is elevated in OGD/R RBMVECs and is regulated by Meg3 via p53. NOX4 regulates levels of HIF1A and VEGF. Thus knockdown of Meg3 acts anti-apoptotic and angiogenic in OGD/R RBMVECs (Zhan et al., 2017).

LncRNA FENDRR induces apoptosis in hypertensive intracerebral hemorrhage (HICH) model of HBMECs treated with thrombin. FENDRR acts as a sponge for miR-126, which can regulate VEGF levels. The study showed that VEGF downregulation could prevent apoptosis of thrombin-treated HBMECs (Dong et al., 2018).

LncRNA Rnst is abundantly expressed in OGD bEnd.3 cells and has a positive correlation with apoptosis while acting as a sponge for miR-150 (Qiao et al., 2020). Another study showed RMST as a ceRNA for miR-204-5p in OGD models for promoting apoptosis. miR-204-5p was shown to target VCAM1 which induced permeability and apoptosis in CVECs (Yin et al., 2021).

Overexpression of lncRNA MIAT induced apoptosis in intracranial aneurysm (IA) model of HBEC-5i cells by upregulating cleaved caspase-3, cleaved PARP1 and Bax, while downregulating Bcl-2. MIAT directly interacts with the MYC proto-oncogene and modulates the expression of the downstream gene Ectodermal-Neural Cortex 1 (ENC1). Silencing Miat and ENC1 independently could prevent apoptosis of cerebrovascular endothelial cells and protect against IA in a rat model (Li et al., 2020).

Apart from the afore-mentioned pathways, several other cerebrovascular endothelial lncRNAs have been reported to date. The entire list of lncRNAs reviewed here can be found in Table 1. We attempt to capture a snapshot of the lncRNA mediated regulation of CVEC pathways in Figure 1.

**STUDYING LNCRNAS IN DIFFERENT BBB MODELS**

This review has compiled studies on lncRNAs in BBB cell culture models and animal models, mostly in various disease contexts.
However, it is widely accepted that the cell culture models of cerebrovascular endothelial cell monolayers or even co-cultures with glial/mural cells are inadequate in representing the blood brain barrier, which is closely regulated by other components of the neurovascular unit. The 2-D and 3-D in vitro models of BBB and in vivo animal models such as rodent and zebrafish models of BBB and their applicability were summarized recently (Bhalerao et al., 2020), (Jackson et al., 2019). Of particular interest in in vitro models is human induced pluripotent stem cell (iPSC)-derived brain microvascular endothelial cell model and multi-cellular organoids which incorporate various cell types of the NVU (Logan et al., 2019), (Lacalle-Aurioles et al., 2020). An intriguing humanized model which involves introduction of human BBB organoids into murine systems has also been explored (Waldau, 2019).

Near identical brain microvasculature across species corresponding to the number of neurons gives a hint that non-human models are good candidates to study BBB function (Wong et al., 2013). Rodent models such as mice and rats are popular models owing to BBB architecture similar to humans, and their evaluation can be done post-mortem or through live techniques such as PET, MRI or two-photon imaging (Jackson et al., 2019). Tissue clearing techniques such as CLARITY and PACT have additionally opened up the possibility of visualizing fixed but intact rodent brain (Tomer et al., 2014), (Woo et al., 2016). The well-annotated invertebrate model Drosophila, has been used to understand BBB dysfunction and drug delivery despite the limited similarity with mammalian system of having only a glial barrier (Cuddapah et al., 2019), (Schirmeier and Klämbt, 2004). An intriguing humanized model which involves introduction of human BBB organoids into murine systems has also been explored (Waldau, 2019).

FUTURE PERSPECTIVES FOR STUDYING LNCRNA IN BBB FUNCTION

The advancements in deep sequencing, with the latest introduction of single-cell sequencing have led to the recording of thousands of novel IncRNAs. The rapidly developing bioinformatic frameworks have also allowed the prediction of biological interactions and functions of IncRNAs. These ambiguous molecules however are experimentally validated in disproportionately lower numbers and this acts as a bottle-neck in understanding their physiologically relevant roles. The past decades have seen the use of genome-editing tools such as TALENs and CRISPR-Cas9 systems to probe functions of novel genes. CRISPR based systems for RNA interference, activation and gene editing have already been tested for high throughput functional screening of IncRNA in erstwhile contexts (Esposito et al., 2019). Further, innovative systems to circumvent effects of conventional CRISPR-Cas9 approaches, including epigenetic silencing and post-transcriptional editing can also help study IncRNA function (Awwad, 2019), (Nuñez et al., 2021). In recent times RNA-editing versions of Cas protein have also emerged, which could be used as a novel strategy (Xu et al., 2020).

A majority of IncRNA functional studies are carried out in cell lines which are amenable to relatively less cumbersome methods of screening. However, as discussed in the previous section, the complex neurovascular unit and the blood brain barrier property as its function is captured limitedly by cell culture based models. Three-dimensional hydrogel based organoids are being explored for modeling the NVU (Potjewyd et al., 2021). The 3D structure will allow emulating the mechanical and biochemical properties of the neurovascular milieu. A recent study successfully developed a vascularized brain organoid model in mice with necessary BBB properties (Cakir et al., 2019). Another recent study has shown the editing using CRISP-Cas9 systems in BBB organoids to identify receptor mediated transcytosis in brain endothelial cells (Simonneau et al., 2021). Therefore in order to study functions of novel IncRNA, BBB organoids can be leveraged by creating gene edited models to understand the role of IncRNA in BBB establishment and maintenance. Further such organoid models can be used for drug screening to identify small molecules that can modulate BBB permeability and function (Bergmann et al., 2018).

In lieu of the poor sequence conservation of IncRNAs, identification of IncRNAs in animal models can illuminate hitherto unknown regulatory angles in well studied pathways. Identification of functionally conserved human IncRNA has been exemplified in the case of IncRNAs jpx (mouse) (Karner et al., 2020) and veal2 (zebrafish) (Sehgal et al., 2021) even in the absence of sequence or structural conservation, albeit with a conserved interacting protein partner. This provides a framework to look beyond sequence-based conservation for identifying IncRNA candidates that regulate well-conserved pathways. Rodent models, which are the most popular models to study BBB physiology have been used to study endothelial and BBB-related IncRNA (Cleuren et al., 2019), (Orsenigo et al., 2020). The very recent cell-type atlas release by the BRAIN Initiative Cell Census Network (BRAIN Initiative Cell Census Network, 2021) that captures nuclear transcriptomic signatures, along with epigenetic state information from mouse motor cortex, adds another powerful dataset for understanding novel transcripts including IncRNA in mammalian brain (BRAIN Initiative Cell Census Network (BICCN), 2021). Zebrafish can be deployed for large functional screens, using anti-sense oligos like morpholinos and CRISPR-based systems (Gut et al., 2017),
Endothelial lncRNA datasets from zebrafish have been reported by several groups (Sehgal et al., 2021), (Müller et al., 2016), while an entire compendium of zebrafish conserved lncRNA is available on the ZFLNC database (Hu et al., 2018). A transcriptome wide sgRNA-guide design may be attempted in zebrafish, coupled with in vivo imaging to track modulations in BBB integrity. The CRISPR toolkit has been proven to be efficient in Xenopus and Drosophila as well, and may well be exploited for understanding lncRNA function in BBB (Bhattacharya et al., 2015), (Port et al., 2020). The drug-based alterations in lncRNA levels in different model systems (Jiang et al., 2019) can further have potential applications in deriving drug-targets among lncRNA identified from BBB.

It can be seen from Table 1 that currently redundant roles have been assigned to a handful of lncRNAs, leaving open the door for functionally validating novel and unannotated candidates. Of note, many of the referred studies have observed that the lncRNA function is exclusive to the respective disease model and does not hold true in the context of homeostasis. Hence, orthogonal validations are needed to strengthen the understanding of lncRNA-mediated regulation of CVEC function. A recent study invalidated several ncRNA studies, underscoring the need to thoroughly test predicted interactions and mechanisms of ncRNA (Mitschka and Mayr, 2021). Stringent and parallel functional validation approaches will allow in confidently placing the lncRNA-mediated regulatory mechanisms in the bigger picture of cerebrovascular endothelial function. We provide a glimpse of the different strategies and models that can be employed for studying lncRNA in cerebrovascular endothelial function in Figure 2.

THERAPEUTIC POTENTIAL OF CVEC LncRNA

LncRNAs are expected to be effective biomarkers and drug targets, due to their low and spatio-temporally restricted expression patterns. This section discusses the expression patterns and levels of lncRNAs and how these correlate with function and ultimately the therapeutic applicability of lncRNA candidates. We further attempt to understand how lncRNAs can be potential therapeutic targets in the context of CVECs.

Expression Patterns of lncRNAs

From 24 human tissues and cell types, Cabili et al. showed that long intergenic RNA (lincRNA), a subset of lncRNA, have highly tissue-specific expression patterns, with the majority having low expression levels. In particular, the brain and testes expressed lncRNAs that are highly tissue-specific. The study reported 4,200 plus lincRNA, and concluded that 78% of lincRNA are tissue-specific, compared to 19% of protein coding genes, after normalizing for expression levels (Cabili et al., 2011). Based on transcriptomic data of 15 human cell lines, compared to protein coding genes, lncRNAs show greater unique expression in cell types (Djebali et al., 2012). The study showed that 10% lncRNA transcripts were found in all cell lines, compared to 29% found in only a single cell line. The corresponding numbers for protein coding transcripts were 53 and 7%. The lower and tissue restricted expression of lncRNAs was replicated during the ENCODE phase 2 project using 16 human tissue samples from RNA-seq data. About 11% of lncRNAs were found in all tissue types, with 65% being the...
corresponding proportion for protein coding transcripts. The study cautions that the tissue-restricted expression may be a false read out owing to the lower expression levels of lncRNAs. The study also used custom microarrays for five human cell lines, 17 tissues and nine region-wise brain samples—all representing a total of 31 cell types—which confirmed lower expression of lncRNAs with respect to protein coding transcripts (Derrien et al., 2012). Further an expression analysis of lncRNAs from The Cancer Genome Atlas (TCGA) including 5,037 samples corresponding to 13 cancer types showed cancer type-specific differential expression of lncRNA (Yan X. et al., 2015). In summary, the understanding of the tissue-specific nature of lncRNAs could be dictated by technical limitations of the detection techniques, however even considering these limitations, the relative abundance is relevant to biological function of lncRNA (Grammatikakis and Lal, 2021). In particular, studies have shown on comparing bulk RNA-sequencing and single cell sequencing that certain lncRNAs are relatively abundantly expressed in a very specific subset of cells, but predictably may show a lower signal in the data from a pool of cells from a tissue (Yan et al., 2013), (Liu et al., 2016).

LncRNA Expression and Apparent Functional Correlation

Depending on the type of function and mode of action, the cellular abundance of a lncRNA may vary. For instance, nuclear localized lncRNAs may be of low abundance if they are cis-acting or trans-acting with specific targets, while trans-acting lncRNAs with genome-wide roles or cytoplasmically localized lncRNA may have relatively higher copy numbers in a cell (~1,000 or more copies per cell) (Grammatikakis and Lal, 2021). Chromatin associated lncRNAs are known to be expressed as low as ~0.3 copies per cell. In comparison protein coding transcript copy numbers lie in the ranges of approximately 10–800 thousands. Thus, the copy number of lncRNA is directly dependent on the kind of function a lncRNA performs (Wu et al., 2021). The quantification of abundance of lncRNA at cellular and tissue-level contexts will be paramount in both determining the function and therapeutic targeting (Kopp and Mendell, 2018). Given that lncRNAs are an amorphous class of molecules with a wide range of functions and varying spatio-temporal abundance, the therapeutic targeting of individual lncRNAs may need customized approaches.

Strategies for Therapeutic Applications of lncRNAs

Clinical trials around the therapeutic potential of lncRNAs have picked up in the past few years. Therapeutic targeting of small non coding RNA such as miRNA has been demonstrated earlier (Winkle et al., 2021), and is being explored in many disease contexts including cerebrovascular conditions such as stroke (Xu Y. et al., 2021). A search for the key word “long non coding RNA” retrieved 69 results on https://www.clinicaltrials.gov/ (As on 27 February 2022). Most of these studies have assessed/intend to assess the potential of lncRNAs as biomarkers in various conditions. Several lncRNAs have already shown potential as biomarkers in cancers (Gutschner et al., 2018). Of note, lncRNAs such as ANRIL and MIAT were primarily identified as differentially expressed transcripts in cardiovascular diseases (Holdt et al., 2010), (Ishii et al., 2006). Hence the applicability of lncRNAs as biomarkers has been well documented and with the increasingly explored transcriptomic data, more and more lncRNA biomarkers may come to the fore.

For considering the potential of lncRNAs as druggable targets, various strategies have been adopted. It has been shown in a phase I clinical trial that lncRNAs of mitochondrial origin can be targeted successfully. FDA approved the use of single-stranded phosphorothioate anti-sense olio (ASO) against anti-sense mitochondrial lncRNA for treatment of solid tumors in advanced metastatic cancer and the ASO was shown to be well tolerated (Chen Y. et al., 2021). A cell-type specific targeting of cancer cells with higher levels of EGFR was shown to be possible by coupling an anti-EGFR aptamer with anti-HOTAI siRNA in a cell line model of triple-negative breast cancer (Wang YL. et al., 2021). The strategies to explore the therapeutic potential of lncRNAs have been reviewed earlier (Renganathan and Felley-Bosco, 2017), (Winkle et al., 2021), (Schwarzmueller et al., 2020). RNA interference, ASO based targeting and CRISPR based targeting are slated to be most effective for modulating levels of lncRNAs (Arun et al., 2018). ASOs have been shown to be effective in mouse disease models against lncRNAs anti-GATA6 (Zhu et al., 2018) and MALAT1 (Arun et al., 2016). Small molecule targeting has also been shown to have some application against lncRNAs such as GASS and MALAT1 (Winkle et al., 2021). This mode of targeting of lncRNAs can be facilitated by understanding the secondary and tertiary structures of lncRNAs and sterically blocking functional motifs (Arun et al., 2018). Combining different approaches of lncRNA targeting have also been attempted (Chen Y. et al., 2021). On the other end, RNA therapeutics where non coding RNAs are used to target another transcript has also been explored. RNA therapeutics can be delivered to the system of interest using carriers and adjuvants, or using viral vectors (Poller et al., 2018). In addition, exosome based and nanoparticles based delivery approaches of RNA therapeutics including delivery of lncRNA in cardiovascular disease are also being tested. Exosome-based delivery can in particular help in cell-specific targeting of RNA therapeutics by incorporating molecules on the exosome membranes that can detect and bind to cell-type specific markers (Lu and Thum, 2019). Intravenous delivery of nRNAs involved in cardiac functioning has been shown to successfully have a therapeutic effect in a mouse model of cardiovascular disease (Quattrocelli et al., 2013).

Targeting CVEC lncRNAs for Therapeutic Applications

The therapeutic applicability of lncRNAs in cerebrovascular diseases has been revealed from transcriptomic analyses. In conditions such as ischemic stroke, differential expression of several lncRNAs could be seen (Deng et al., 2018), and the levels of H19, ANRIL, NEAT1 and other candidate lncRNAs
seem to correlate with the severity of stroke (Gan et al., 2020). These lncRNAs showed marked upregulation in ischemic stroke and are considered as biomarkers. Possibilities of targeting lncRNAs across cardiovascular diseases have been reviewed earlier (Gomes et al., 2017). Small molecule based targeting in cardiac arrhythmias have been shown to lead to lowering of the levels of lncRNAs exacerbating the disease (Zhang Y. et al., 2019).

As described before, BBB dysfunction can lead to neurological conditions and vice versa. It is therefore important to look at therapeutic interventions that can manage potential breach of the blood brain barrier. Some of the approaches to prevent excessive permeability of the BBB is by targeting the VEGF pathway players and the downstream matrix metalloproteases. Further the use of antago-miRs and small molecules that can elevate levels of junctional proteins of the endothelial cells have also been proven effective (Archie et al., 2021). Engineered Wnt ligands have also been shown to be effective in preventing deterioration of BBB properties in conditions such as glioblastoma and stroke (Martin et al., 2022). This review has described CVEC lncRNAs across different pathways including VEGF and Wnt-related pathways. Targeting of lncRNAs that are potential modulators of such pathways which have already been shown to have drug targets to modulate BBB function provides a framework to explore novel therapeutic mechanisms in BBB dysfunction.

Increasing number of transcriptomic studies, especially at single cell resolution, are identifying unique EC differentiating patterns providing opportunities to specifically target ECs subtypes such as CVECs. Single cell sequencing of cells from brain vasculature of mice could identify unique transcriptomic signatures in endothelial cells, microglia, oligodendrocytes and fibroblasts (Lin et al., 2021). Cerebrovascular endothelial cells themselves have been shown to be heterogeneous in a cerebral cavernous malformation mouse model (Orsenigo et al., 2020). Five distinct EC types were identified from single cell sequencing of glioblastoma (GBM) tumor vessels from human patients. The EC phenotypes showed varying breakdown extents of the blood brain barrier property. Additionally, the ECs isolated from GBM tissue showed different gene signatures than ECs isolated from peripheral brain tissue (Xie et al., 2021). While these studies did not explicitly shed light on the non-coding RNA players, it will be interesting to see future studies on the lncRNA markers across CVEC sub-populations. This can pave the way for cell type-specific targeting of CVEC lncRNA using approaches such as exosome-based delivery of ASOs or RNA therapeutics (Lu and Thum, 2019).

**Current Challenges in Therapeutic Targeting of lncRNAs**

While low copy numbers of lncRNAs that can be targeted can be an advantage because they may need lower dosages of targeting agents, there are several challenges to be tackled. One of the primary considerations in lncRNA targeting is the appropriate classification of lncRNAs based on abundance, processing, function and structure for designing therapeutics to each class for better effectiveness (Poller et al., 2018). As mentioned earlier, signals from bulk RNA sequencing may give a misleading read out on the cell types from expressing lncRNA. With the widespread use of single cell sequencing, this limitation can be overcome in the near future. Alternatively, visualization techniques such as fluorescence in situ hybridization can hint at a cellular subset-specific origin of a lncRNA. Further, a known functional relevance of lncRNA and proven conserved function if discovered in a model organism can be factors imperative for selection of a lncRNA therapeutic target (Gutschner et al., 2018). An additional consideration for RNA therapeutics based targeting of lncRNAs is the immunogenicity and toxicity of such agents, apart from issues of stability, specificity and delivery (Winkle et al., 2021), (Chen Y. et al., 2021). Hence, testing the therapeutic potential of lncRNAs may need several layers of examination and clear understanding of the molecular mechanism across a variety of models and conditions.

**CONCLUSION**

The homeostasis of cerebrovascular endothelial cells forming the blood brain barrier is under the complex regulation of multiple pathways, which are primarily dictated by surrounding cells and various local environmental cues. This allows CVECs to exhibit dynamism. Many lncRNAs have been shown to perform a regulatory role in cellular processes of CVECs, suggesting the presence of an under-studied mechanistic layer added by lncRNAs in CVEC function. Adopting appropriate models mimicking the cerebrovascular endothelial cells, blood-brain barrier and neurovascular unit can be an important strategy to gain a true picture of the underlying mechanisms of lncRNAs. The past decades have seen lncRNA studies that have mostly focused on a small subset of highly and ubiquitously expressed lncRNAs that are technically easier to probe with the available strategies to understand lncRNA function. This review is a compendium of several such studies that have cataloged the functional mechanism of lncRNAs in CVECs that could have redundant or overlapping roles in other cell types as well. With an increase in the annotation of the thousands of novel lncRNAs identified from bulk RNA sequencing and cell-type specific sequencing, in the future CVEC specific lncRNA signature may emerge that can be specifically targeted in the context of maintaining and modulating the blood brain barrier.

**AUTHOR CONTRIBUTIONS**

SM performed the literature review. The manuscript was written by SM and SS. The figures were illustrated by SM.

**FUNDING**

This work was supported by Council of Scientific and Industrial Research (CSIR), India (Grant number MLP 2001). SM acknowledges CSIR, India, for Senior Research Fellowship.
REFERENCES

Aird, W. C. (2007a). Phenotypic Heterogeneity of the Endothelium. Circ. Res. 100, 158–173. doi:10.1161/01.RES.0000255691.76142.4a
Aird, W. C. (2007b). Phenotypic Heterogeneity of the Endothelium. Circ. Res. 100, 174–190. doi:10.1161/01.RES.0000255690.03436.a

Archie, S. R., Al Shoyab, A., and Cucullo, L. (2021). Blood-Brain Barrier Dysfunction in CNS Disorders and Putative Therapeutic Targets: An Overview. Pharmaceuticals 13, 1779. doi:10.3390/pharmaceuticals13111779

Argaw, A. T., Asp, L., Zhang, J., Navrazhina, K., Pham, T., Mariani, J. N., et al. (2012). Astrocyte-derived VEGF-A Drives Blood-Brain Barrier Disruption in CNS Inflammatory Disease. J. Clin. Invest. 122, 2454–2468. doi:10.1172/JCI60842

Argaw, A. T., Gurfein, B. T., Zhang, Y., Zameer, A., and John, G. R. (2009). VEGF-B Mediated Disruption of Endothelial CLN-5 Promotes Blood-Brain Barrier Breakdown. Proc. Natl. Acad. Sci. U.S.A. 106, 1977–1982. doi:10.1073/pnas.0808698106

Arun, G., Diermeier, S., Akerman, M., Chang, K.-C., Wilkinson, J. E., Hearns, S., et al. (2016). Differentiation of Mammary Tumors and Reduction in Metastasis upon Malat1 LncRNA Loss. Genes Dev. 30, 34–51. doi:10.1101/gad.178059.115

Arun, G., Diermeier, S. D., and Spector, D. L. (2018). Therapeutic Targeting of Long Non-coding RNAs in Cancer. Trends Mol. Med. 24, 257–277. doi:10.1016/j.molmed.2018.01.001

Awad, D. A. (2019). Beyond Classic Editing: Innovative CRISPR Approaches for Functional Studies of Long Non-coding RNA. Biol. Methods Protoc. 4, e00177. doi:10.1093/biometools/bpz017

Bahrami, N., and Childs, S. J. (2018). Pericyte Biology in Zebrafish. Adv. Exp. Med. Biol. 1109, 33–51. doi:10.1007/978-3-030-02601-1_4

Bai, Y., Zhu, X., Chao, J., Zhang, Y., Qian, C., Li, P., et al. (2015). Pericytes Contribute to the Disruption of the Cerebral Endothelial Barrier via Increasing VEGF Expression: Implications for Stroke. PLoS One 10, e0142362. doi:10.1371/journal.pone.0142362

Bauer, H.-C., Krizbai, I. N. A., Bauer, H., and Traweger, A. (2014). β-Interferon Contributes to the Disruption of the Cerebral Endothelial Barrier via Increasing VEGF Expression: Implications for Stroke. PLoS One 10, e0142362. doi:10.1371/journal.pone.0142362

De Jesus Andino, F., Jones, L., Maggirwar, S. B., and Robert, J. (2016). Frog Virus 3 Dissemination in the Brain of Tadpoles, but Not in Adult Xenopus, Involves Blood Brain Barrier Dysfunction. Sci. Rep. 6, 22508. doi:10.1038/srep22508

Deng, Q.-W., Li, S., Wang, H., Sun, H.-L., Zuo, L., Gu, Z.-T., et al. (2018). Differential Long Non-coding RNA Expression in Peripheral Blood Mononuclear Cells for Detection of Acute Ischemic Stroke. Clin. Sci. Lond. Engl. 132, 1997–2014. doi:10.1042/CS20180411

Deng, W., Fan, C., Shen, R., Wu, Y., Du, R., and Teng, J. (2020). Long Noncoding MIAT Acting as a ceRNA to Sponge microRNA-204-5p to Participate in Cerebral Microvascular Endothelial Cell Injury after Cerebral Ischemia through Regulating HMGBl. J. Cell. Physiol. 235, 4571–4586. doi:10.1002/jcp.29334

Derrien, T., Johnson, R., Bussotti, G., Tanzer, A., Djebali, S., Tilgner, H., et al. (2012). The GENCODE V7 Catalog of Human Long Noncoding RNAs: Analysis of Their Gene Structure, Evolution, and Expression. Genome Res. 22, 1775–1789. doi:10.1101/gr.121591.111

Djebali, S., Davis, C. A., Merkel, A., Dobin, A., Lassmann, T., Mortazavi, A., et al. (2014). Patterns of DNA Methylation in Human LncRNA Gene Bodies. Nature 515, 285–290. doi:10.1038/nature13877

Dong, B., Zhang, Y., Guo, J., and Sun, Y. (2011). lncRNA-Mediated VEGF Regulation in Human Cancer. Trends Mol. Med. 17, 319–326. doi:10.1016/j.molmed.2010.12.003

Dragoni, S., and Turowski, P. (2018). Polarised VEGF Signalling at Vascular Blood-Neural Barriers. IJms 19, 1378. doi:10.3390/ijms19051378

Esposito, R., Bosch, N., Lanzos, A., Poldori, T., Pulido-Quetglas, C., and Johnson, R. (2019). Hacking the Cancer Genome: Profiling Therapeutically Actionable Long Non-coding RNAs Using CRISPR-Cas9 Screening. Cancer Cell 35, 545–557. doi:10.1016/j.ccell.2019.01.019

Fang, S., Zhang, L., Guo, J., Liu, Y., Wu, Y., Li, H., et al. (2018). NONCODEv5: A Comprehensive Annotation Database for Long Non-coding RNAs. Nucleic Acids Res. 46, D308–D314. doi:10.1093/nar/gkx1107
Li, Y.-N., Pan, R., Qin, X.-J., Wang, Y.-L., Qi, Z., Liu, W., et al. (2014b). Ischemic Neurons Activate Astrocytes to Disrupt Endothelial Barrier via Increasing VEGF Expression. J. Neurochem. 129, 120–129. doi:10.1111/jn.12611

Li, Y., Chen, T., Miao, X., Yi, X., Wang, X., Zhao, H., et al. (2017a). Zebrafish: A Promising In Vivo Model for Assessing the Delivery of Natural Products, Fluorescence Dyes and Drugs across the Blood-Brain Barrier. Pharmacolet. Res. 125, 246–257. doi:10.1016/j.phrs.2017.08.017

Li, Z., Li, J., and Tang, N. (2017b). Long Noncoding RNA MALAT1 Is a Potent Autophagy Inducer Protecting Brain Microvascular Endothelial Cells against Oxygen-Glucose Deprivation/reoxygenation-Induced Injury by Sponging miR-26b and Upregulating ULK2 Expression. Neuroscience 354, 1–10. doi:10.1016/j.neuroscience.2017.04.017

Lin, W.-W., Xu, L.-T., Chen, Y.-S., Go, K., Sun, C., and Zhu, Y.-J. (2021). Single-Cell Transcriptomics-Based Study of Transcriptional Regulatory Features in the Mouse Brain Vasculature. Biomed. Res. Int. 2021, 1–15. doi:10.1155/2021/7643209

Liu, S. J., Nowakowski, T. J., Pollen, A. A., Lui, J. H., Horlbeck, M. A., Attelanno, F., J., et al. (2016). Single-cell Analysis of Long Non-coding RNAs in the Developing Human Neocortex. Genome Biol. 17, 67. doi:10.1186/s13059-016-0932-1

Liu, X., Shen, L., Han, B., and Yao, H. (2021). Involvement of Noncoding RNA in Blood-Brain Barrier Integrity in central Nervous System Disease. Non-coding RNAs in Cardiovascular Disease: Diagnostic and Therapeutic Perspectives. Eur. Heart J. 39, 2704–2716. doi:10.1093/eurheartj/ehz165

Logan, S., Arzua, T., Canfield, A., Shen, L., Han, B., and Yao, H. (2021). Involvement of Noncoding RNA in Cardiovascular Diseases: Diagnostic and Therapeutic Perspectives. Adv. Exp. Med. Biol. 1008, 199–207. doi:10.1007/978-981-10-5203-3_7

Ma, J., Wang, P., Yao, Y., Liu, Y., Li, Z., Liu, X., et al. (2016). Knockdown of Long Non-coding RNA MALAT1 Increases the Blood-Tumor Barrier Permeability by Up-Regulating miR-140. Biochim. Biophys. Acta (BBA) - Gene Regul. Mech. 1859, 324–338. doi:10.1016/j.bjgrm.2015.11.008

Ma, Y., Wang, P., Xue, Y., Qu, C., Zheng, J., Liu, X., et al. (2017a). PVT1 Affects Growth of Glioma Microvascular Endothelial Cells by Negatively Regulating miR-186. Tumour Biol. 39, 1010428317694326. doi:10.1177/1010428317694326

Ma, Y., Xue, Y., Liu, X., Qu, C., Cai, H., Wang, P., et al. (2017b). SNHG15 Affects the Growth of Glioma Microvascular Endothelial Cells by Negatively Regulating miR-153. Oncol. Rep. 38, 3265–3277. doi:10.3892/or.2017.5985

Mäe, M. A., He, L., Nording, S., Vazquez-Liebanas, E., Nahar, K., Jung, B., et al. (2021). Single-Cell Analysis of Blood-Brain Barrier Response to Pericyte Loss. Circ. Res. 128, 130–138. doi:10.1161/CIRCRESAHA.120.317473

Martin, M., Vermeiren, S., Bostaille, N., Eubelen, M., Spitzer, D., Vermeersch, M., et al. (2022). Engineered Wnt Ltnads Enable Blood-Brain Barrier Repair in Neurological Disorders. Science 375, eabm4459. doi:10.1126/science.abd4459

Mathiassen, S. G., De Zio, D., and Cecconi, F. (2017). Autophagy and the Cell Cycle: A Complex Landscape. Front. Oncol. 7, 51. doi:10.3389/fonc.2017.00051

McDonell, P., and Guttman, M. (2019). Approaches for Understanding the Mechanisms of Long Noncoding RNA Regulation of Gene Expression. Cold Spring Harb. Perspect. Biol. 11, a032151. doi:10.1101/cshperspect.a032151

Mitschka, S., and Mayr, C. (2021). Endogenous P53 Expression in Human and Mouse Is Not Regulated by its 3′UTR. Cell. Life, e65700. doi:10.7554/eLife.65700

Müller, R., Weirick, T., John, D., Militello, G., Chen, W., Dimmeler, S., et al. (2016). Developing Human Neocortex. Circ. Res. 118, 1520–1532. doi:10.1161/CIRCRESAHA.116.305759

Mitschka, S., and Mayr, C. (2021). Endogenous P53 Expression in Human and Mouse Is Not Regulated by its 3′UTR. CellLife, e65700. doi:10.7554/eLife.65700

O apo, P., Yan, H., and Wang, J. (2020). EGb761 Protects Brain Microvascular Endothelial Cells against Oxygen-Glucose Deprivation-Induced Injury through LncRNA Rmst/miR-150 Axis. Neurochem. Res. 45, 2398–2408. doi:10.1007/s11064-020-03099-8

Quattrociocchi, M., Crippa, S., Montecchiani, C., Camps, J., Cornaglia, A. L., Boldrin, L., et al. (2013). Long-Term miR-669a Therapy Alleviates Chronic Dilated Cardiomyopathy in Dystrophic Mice. J. AHA. 113. 002804

Quinn, J. J., and Chang, H. Y. (2016). Unique Features of Long Non-coding RNA Biogenesis and Function. Nat. Rev. Genet. 17, 47–62. doi:10.1038/nrg.2015.10

Ranjan, G., Sehgal, P., Sharma, D., Scarra, V., and Sivasubbu, S. (2021). Functional Long Non-coding Circular RNAs in Zebrfish. Brief. Funct. Genomics 1, elab014. doi:10.1093/bfgp/elab014

Renganathan, A., and Felley-Bosco, E. (2017). Long Noncoding RNAs in Cancer and Therapeutic Potential. Adv. Exp. Med. Biol. 1008, 199–222. doi:10.1007/978-981-10-5203-3_7

Rizzo, M. T., and Leaver, H. A. (2010). Brain Endothelial Cell Death: Modes, Signaling Pathways, and Relevance to Neural Development, Homeostasis, and Disease. Mol. Neurobiol. 42, 52–63. doi:10.1007/s12035-010-8132-6

Sa, L., Li, Y., Zhao, L., Liu, Y., Wang, P., Liu, L., et al. (2017). The Role of HOTAIR/miR-148b-3p/USF1 on Regulating the Permeability of BTB. Front. Mol. Neurosci. 10, 194. doi:10.3389/fnmol.2017.00194

Sabbagh, M. F., Heng, J. S., Luo, C., Castanon, R. G., Nery, J. R., Rattner, A., et al. (2018). Transcriptional and Epigenomic Landscapes of CNS and Non-CNS Vascular Endothelial Cells. eLife 7, e36187. doi:10.7554/eLife.36187

Schirmeier, S., and Klämbt, C. (2015). The Drosophila Blood-Brain Barrier as Interface between Neurons and Hemolymph. Mech. Development 138 (Pt 1), 50–55. doi:10.1016/j.mod.2015.06.002

Schwarzmueller, L., Bril, O., Vermeulen, L., and Lévéillé, N. (2020). Emerging Role and Therapeutic Potential of IncRNAs in Colorectal Cancer. Cancers 12, 3843. doi:10.3390/cancers12123843

Sehgal, P., Mathew, S., Sivadas, A., Ray, A., Tanwar, J., Vishwakarma, S., et al. (2021). LncRNA VEAL2 Regulates PRKCB2 to Modulate Endothelial Permeability in Diabetic Retinopathy. EMBO J. 40, e107134. doi:10.15222/embj.2020107134

Shen, B., Wang, L., Xu, Y., Wang, H., and He, S. (2021). LncRNA GAS5 Silencing Attenuates Oxygen-Glucose Deprivation/Reperfusion-Induced Injury in Brain Microvascular Endothelial Cells via miR-34b-3p-dependent Regulation of EPHA4. Nfd 17, 1667–1678. doi:10.2147/NFD.S02314

Shen, S., Yu, H., Liu, X., Liu, Y., Zheng, J., Wang, P., et al. (2018). PIWILL1/pRNA-DQ539103 Regulates the Permeability of the Blood-Tumor Barrier via the
Zhang, L., Luo, X., Chen, F., Yuan, W., Xiao, X., Zhang, X., et al. (2018a). LncRNA SNHG1 Regulates Cerebrovascular Pathologies as a Competing Endogenous RNA through HIF-1α/VEGF Signaling in Ischemic Stroke. J. Cel Biochem. 119, 5460–5472. doi:10.1002/jcb.26705

Zhang, L., Yang, H., Li, W.-J., and Liu, Y.-H. (2020b). LncRNA MALAT1 Promotes OGD-Induced Apoptosis of Brain Microvascular Endothelial Cells by Sponging miR-126 to Repress PI3K/Akt Signaling Pathway. Neurochem. Res. 45, 2091–2099. doi:10.1007/s11064-020-03071-6

Zhang, M., Tang, M., Wu, Q., Wang, Z., Chen, Z., Ding, H., et al. (2020c). LncRNA DANCR Attenuates Brain Microvascular Endothelial Cell Damage Induced by Oxygen-Glucose Deprivation through Regulating of miR-33a-5p/XBP1s. Aging 12, 1778–1791. doi:10.18632/aging.102712

Zhang, S., An, Q., Wang, T., Gao, S., and Zhou, G. (2018b). Autophagy- and MMP-2/9-Mediated Reduction and Redistribution of ZO-1 Contribute to Hyperglycemia-Increased Blood-Brain Barrier Permeability during Early Reperfusion in Stroke. Neuroscience 377, 126–137. doi:10.1016/j.neuroscience.2018.02.035

Zhang, T., Wang, H., Li, Q., Fu, J., Huang, J., and Zhao, Y. (2018c). MALAT1 Activates the P53 Signalin g Pathway by Regulating MDM2 to Promote Ischemic Stroke. Cell Physiol Biochem 50, 2216–2228. doi:10.1159/000495083

Zhang, X., Tang, X., Liu, K., Hamblin, M. H., and Yin, K.-J. (2017b). Long Noncoding RNA Malat1 Regulates Cerebrovascular Pathologies in Ischemic Stroke. J. Neurosci. 37, 1797–1806. doi:10.1523/JNEUROSCI.3389-16.2017

Zhang, Y., Du, W., and Yang, B. (2019b). Long Non-coding RNAs as New Regulators of Cardiac Electrophysiology and Arrhythmias: Molecular Mechanisms, Therapeutic Implications and Challenges. Pharmacol. Ther. 203, 107389. doi:10.1016/j.pharmthera.2019.06.011

Zhao, M., Wang, J., Xi, X., Tan, N., and Zhang, L. (2018). SNHG12 Promotes Angiogenesis Following Ischemic Stroke via Regulating miR-150/VEGF Pathway. Neuroscience 390, 231–240. doi:10.1016/j.neuroscience.2018.08.029

Zhou, Z.-W., Zhang, L.-J., Ren, X., Li, A.-P., and Zhou, W.-S. (2019). LncRNA NEAT1 Facilitates Survival and Angiogenesis in Oxygen-Glucose Deprivation (OGD)-induced Brain Microvascular Endothelial Cells (BMECs) via Targeting miR-377 and Upregulating SIRT1, VEGFA, and BCL-XL. Brain Res. 1707, 90–98. doi:10.1016/j.brainres.2018.10.031

Zhu, P., Wu, J., Wang, Y., Zhu, X., Lu, T., Liu, B., et al. (2018). LncGata6 Maintains Stemness of Intestinal Stem Cells and Promotes Intestinal Tumorigenesis. Nat. Cel Biol. 20, 1134–1144. doi:10.1038/s41556-018-0194-0

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Mathew and Sivasubbu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
ULK2  Unc-51 Like Autophagy Activating Kinase 2
USF1  Upstream stimulatory factor 1
VCAM-1  Vascular cell adhesion protein 1
VEAL2  Vascular endothelial associated lncRNA-2
VEGF  Vascular endothelial growth factor
VEGFR  Vascular endothelial growth factor receptor
XIST  X-inactive specific transcript
YBX1  Y box binding protein 1
ZAK  ZO-1-associated kinase
ZO  Zona occludens